Tirzepatide (Micro) 1mg-2mg

Timing: Before Bed

Frequency: Weekly

Protocol: 1mg-2mg

Uses

• Management of Gastrointestinal Effects: Using smaller, initial doses may allow the body to adapt gradually to the medication, potentially minimizing common side effects such as nausea, vomiting, and diarrhea.
• Appetite Regulation: Lower doses may provide subtle appetite regulation and hunger management without causing extreme appetite suppression, according to anecdotal reports.
• Metabolic Support: Activating GIP and GLP-1 receptors, even at lower levels, may assist with improving insulin sensitivity and stabilizing blood sugar, which is particularly relevant for managing metabolic conditions, including those associated with PCOS or hormonal changes.
• Gradual Weight Management: A slower titration schedule may be used t

Benefits

• Significant weight loss, typically greater than other GLP-1 medications
• Improved blood sugar control and insulin sensitivity
• Reduced appetite and fewer food cravings
• Improved cholesterol and triglyceride levels
• Modest blood pressure reduction
• May improve sleep apnea symptoms in clients with obesity
• Cardiovascular and metabolic health support tied to weight reduction

Contraindications

Thyroid Cancer History

• Personal history of medullary thyroid carcinoma
• Family history of medullary thyroid carcinoma
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

Pancreatic Conditions

• History of pancreatitis
• Active gallbladder disease or gallstones

Gastrointestinal conditions

• Gastroparesis (delayed stomach emptying)
• Severe GERD or chronic vomiting
• Inflammatory bowel disease (flag for clinician review)

Eating disorders

• Bulimia (current or past)
• Anorexia Nervosa (current or past)

Pregnancy and fertility

• Currently pregnant
• Planning pregnancy in the near term
• Breastfeeding

Diabetes-specific cautions

• Type 1 diabetes
• History of diabetic retinopathy (flag for clinician review)
• Currently taking insulin or sulfonylureas (hypoglycemia risk, clinician must review)

Other

• Prior serious allergic reaction to tirzepatide or semaglutide
• Severe kidney disease (flag for clinician review)
• History of suicidal ideation (flag for clinician review)